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Traumatic brain injury 1
Severe traumatic brain injury: targeted management in the 
intensive care unit
Nino Stocchetti, Marco Carbonara, Giuseppe Citerio, Ari Ercole, Markus B Skrifvars, Peter Smielewski, Tommaso Zoerle, David K Menon
Severe traumatic brain injury (TBI) is currently managed in the intensive care unit with a combined medical–
surgical approach. Treatment aims to prevent additional brain damage and to optimise conditions for brain recovery. 
TBI is typically considered and treated as one pathological entity, although in fact it is a syndrome comprising a 
range of lesions that can require different therapies and physiological goals. Owing to advances in monitoring and 
imaging, there is now the potential to identify specific mechanisms of brain damage and to better target treatment 
to individuals or subsets of patients. Targeted treatment is especially relevant for elderly people—who now represent 
an increasing proportion of patients with TBI—as preinjury comorbidities and their therapies demand tailored 
management strategies. Progress in monitoring and in understanding pathophysiological mechanisms of TBI 
could change current management in the intensive care unit, enabling targeted interventions that could ultimately 
improve outcomes.
Introduction
Traumatic brain injury (TBI) is a major cause of death 
and disability worldwide, with more than 13 million 
people estimated to live with disabilities related to TBI in 
Europe and the USA.1 About 10–15% of patients with 
TBI have serious injuries that require specialist care.2 
Patients with severe grades of TBI are commonly 
managed in the intensive care unit (ICU)3 with a 
combined medical–surgical approach that has changed 
little over the past 20 years. A reassessment of this area 
of clinical practice is warranted on several grounds. 
First, recent expert reappraisals of such care have 
indicated that the evidence supporting most inter­
ventions is weak or non­existent,4 with few randomised 
controlled trials (RCTs) to guide treatment decisions. In 
view of this dearth of evidence­based medicine to 
underpin clinical care, clinicians have had to rely on 
best­practice statements from expert bodies, based on 
decades of accumulated and refined clinical experience.5 
Moreover, treatment targets incorporated into guide lines 
are usually derived from population studies and applied 
to all patients with TBI in the ICU. This approach 
reduces management variability but ignores differences 
in underlying pathological features. TBI is, in fact, a 
syndrome that includes a range of brain lesions with 
separate—sometimes diverging—patho physiological 
pathways and therapeutic needs. As a result, 
undifferentiated interventions aimed at the overall 
population with TBI, rather than targeted to specific 
disease mechanisms and groups of patients, are likely to 
fail, as exemplified by repeated failures of clinical trials 
of neuroprotective agents.6
Furthermore, many patients with TBI who are now 
treated in the ICU differ greatly from those individuals 
from whom much of our accumulated clinical experience, 
research, and guidelines have been derived—ie, young 
(typically male) patients who sustained a TBI from 
high­velocity traffic injuries or assault. In high­income 
countries, TBI affects increasing proportions of people 
older than 65 years (who we arbitrarily indicate as 
elderly)—eg, in the USA, the rate of TBI­related hospital 
admissions for elderly people has risen by more than 50% 
from 2001 to 2010,7 whereas this rate has remained stable 
or declined for individuals aged 15–44 years. This 
epidemiological change reflects increased life expectancy8 
coupled with risk factors typical of elderly people, such as 
age­related comorbidities and their pharmacological 
treatment. These older patients typically present after 
having sustained falls from a fairly low height, and the 
clinical course of these TBIs is complicated by multiple 
comorbidities and their treatment.
In this Review, we briefly describe the heterogeneity of 
pathological and pathophysiological features of TBI seen 
in the ICU, discuss how we might organise rational 
clinical care in view of the scarcity of conventional 
evidence from RCTs, and postulate how we could 
individualise care to aim for precision medicine 
approaches, considering pathophysiological diversity 
with use of advances in monitoring techniques. We focus 
on severe TBI in adults and, importantly, in addressing 
each of these issues, we examine how the rising age of 
patients with TBI in the ICU might require new evidence 
to strengthen clinical management.
Pathological and pathophysiological features
Primary and secondary injury
TBI is divided classically into two distinct phases: 
primary injury followed by delayed secondary injury. 
Primary injury arises from external physical forces 
applied to the head producing skull fractures, 
haematomas, and deformation and destruction of brain 
tissue, including contusions and axonal injury. Secondary 
injury develops over time with activation of multiple 
molecular and cellular pathways.9,10 Axonal stretching 
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during injury can cause dysregulation of transmembrane 
ion fluxes and impaired axonal transport, and damaged 
axons could be vulnerable to secondary axotomy and 
demyelination. Changes in ionic permeability and release 
of excitatory neurotransmitters, particularly glutamate, 
propagate damage through energy failure and overload 
of free radicals. Altered cellular permeability also 
increases calcium influx, which causes mitochondrial 
dysfunction, triggering further energy defects and 
necrotic and apoptotic processes.10
These molecular and cellular changes might lead to 
development of cytotoxic or vasogenic brain oedema and 
disturbed auto regulation, whereby the volume of 
intracranial contents grows because of vascular dilation 
or water accumulation, or both.11 Once this volume 
increase exceeds the compensatory capacities of the 
intracranial space, intracranial pressure (ICP) rises. 
Seizures early after trauma can exacerbate the imbalance 
between energy expenditure and supply.12 Another 
electrical disturbance—spreading depolarisation—can 
occur in patients with TBI, and might be responsive to 
glutamate antagonists. Spreading depolarisation leads to 
anaerobic metabolism and energy substrate depletion, 
and it also seems to be associated with a worse outcome.13
Trauma affects the blood–brain barrier directly, with 
increased permeability favouring vasogenic oedema 
formation and activation of a proinflammatory state.14 
Inflammation, also promoted by resident microglia, 
could provide neuroprotection or aggravate secondary 
injury.14 Patients with TBI often have extracranial injuries 
(eg, fractures and chest and abdominal trauma) and 
massive bleeding. These can cause hypoxia or arterial 
hypo tension and trigger a systemic inflammatory 
response syndrome that can further aggravate the 
development of secondary injury.15 This complex series of 
events starts minutes after trauma but lasts for weeks or 
even months, particularly for inflammation.16
Heterogeneity of TBI
TBI is typically classified according to clinical severity, 
with severe injury usually categorised on the basis of a 
total Glasgow Coma Scale (GCS) score of 8 or less.17 TBI 
produces various lesions that range from mild injury 
to devastating damage. Expanding haematomas—
extradural or subdural—might need emergency 
surgical removal in the first hours after injury; 
intraparenchymal contusions can increase over hours 
or days and need surgery as well. More subtle lesions 
such as traumatic axonal injury (the term commonly 
used, diffuse axonal injury, strictly only applies when 
involving three or more locations18) might not be 
evident from initial CT scans but, owing to neuronal 
network disruption, might have a serious effect on the 
quality of life of survivors, and can be seen on MRI.19 
These different lesion types typically arise in 
combination: for instance, cerebral contusions can 
develop underneath a subdural haematoma, and might 
also be associated with axonal injury. Figure 1 shows 
how the risk of high ICP, mortality, and disability can 
vary by lesion type.20–23
Several biomarkers of neuronal injury (eg, neuron­
specific enolase, ubiquitin C­terminal hydrolase L1, 
spectrin breakdown products), axonal injury (eg, tau 
protein, neurofilaments), and glial injury (eg, glial 
fibrillary acidic protein, S100β) in serum and CSF are 
being investigated in patients with TBI.24,25 These 
markers could—either individually or in combination—
be used to characterise injury severity and type, and they 
might have prognostic importance.24,25 Although 
preliminary evidence of cost­effectiveness is emerging 
for some biomarkers in mild TBI, their role in more 
severe injury remains uncertain. We need large­scale 
studies of the most promising biomarkers (or panels of 
biomarkers) to determine whether they can be used to 
refine initial characterisation of brain damage in 
critically ill patients with TBI.
Specific features of TBI in elderly people
TBI in older patients typically results from low­energy 
impacts such as ground­level falls,26 with a higher 
Figure 1: Heterogeneity of traumatic brain injury
Road accidents, intentional injuries, and falls can cause different types of head lesion; together with skull fractures, 
various parenchymal and vascular injuries often coexist. In this schematic diagram, lesions are presented separately 
for the purpose of classification, and estimates of risk of high ICP, mortality, and disability are shown. Some lesions, 
such as subdural haematomas, entail a substantial risk of elevated ICP, whereas others, such as axonal injury, are 
associated rarely with ICP disturbances20 but might have a very severe effect on outcome. Axonal damage in 
multiple brain regions causes impairments in cognitive, motor, and sensory functions by disrupting neuronal 
connectivity. Pathological masses, such as contusions or intracranial haematomas, can vary in size and in their 
tendency to expand. When large pathological volumes accumulate, further compressing the brain, the probability 
of an unfavourable outcome, with high mortality and severe disability, is raised. Other vascular injuries, such as 
major vessel dissection or traumatic aneurysms, perhaps underdiagnosed with routine imaging, can be detected 
with appropriate investigations.21 Mortality and disability are associated with several factors, such as age, 
comorbidities, and location and extent of the traumatic injury. Similarly, ICP rises might depend on multiple 
disturbances, such as hyponatraemia, and not just on the initial anatomical damage. Information on outcomes is 
from the IMPACT study.22,23 ICP=intracranial pressure. SAH=subarachnoid haemorrhage. TBI=traumatic brain injury.
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proportion of subdural haematomas and fewer 
contusions or epidural haematomas in this group than 
in younger patients.27,28 Cerebral atrophy and increased 
CSF space could buffer new pathological intracranial 
masses, which could be linked to a lower incidence of 
raised ICP.29,30 The GCS might underestimate the 
severity of brain injury in elderly patients,31 making a 
case for higher score thresholds to trigger triage of 
older patients to specialist centres.32 Furthermore, age­
related comorbidities (eg, diabetes, chronic cardio­
respiratory disease, and renal dysfunction) reduce 
physiological reserve and increase the incidence and 
severity of brain damage due to second insults such as 
hypoxia and hypotension. Many of the treatments used 
for these chronic diseases (in particular, anticoagulant 
and antiplatelet drugs) might increase risk of 
haemorrhage or could worsen the evolution of 
intracerebral traumatic lesions (with the greatest risk 
from vitamin K antagonists).33 Finally, the diminished 
brain reserve in these older patients34 limits the 
potential for plasticity and neural repair and, hence, 
hampers the success of rehabilitation. The main 
differences between younger and older patients with 
TBI are summarised in the panel.34–44
Fundamentals of ICU monitoring and 
management 
Patients with severe TBI are currently treated in the ICU 
with a specialised neurointensive approach combined 
with strategies used in general intensive care such as 
early enteral feeding, infection control and treatment, 
normalisation of respiratory exchanges with skilled 
nursing, physiotherapy, and artificial ventilation, and 
fluid optimisation for arterial pressure and splanchnic 
organ perfusion. This approach aims to prevent second 
insults and maintain cerebral homoeostasis. Some 
current strategies entail targeted approaches—eg, 
surgical haematoma removal—whereas many medical 
therapies (for instance, treatments for controlling high 
ICP) are prescribed for all cases.
Prevention of second insults
Prevention of second insults involves addressing both 
systemic threats (eg, hypoxia, hypercapnia, arterial 
hypotension, hyponatraemia, and pyrexia) and 
intracranial threats (eg, expanding haematomas or 
contusions and ICP rises). In this section, we focus on 
intracranial threats, which can be detected through 
clinical examination and ICP monitoring.
Panel: Main differences between young adults and elderly people with traumatic brain injury
Preinjury factors
•	 Comorbidities are common in elderly people but rare in young 
adults with traumatic brain injury (TBI). Diabetes, chronic 
heart and renal failure, and chronic obstructive pulmonary 
disease might all increase the risk of systemic complications 
and second insults such as hypoxia and hypotension.
•	 Anticoagulant	and	antiplatelet	drugs	are	used	increasingly	
in the general population,35 and particularly in elderly 
people; these drugs increase the risk of cerebral 
haemorrhagic lesions and might worsen the expansion of 
initial bleeding, even after modest TBIs.36,37
•	 Polypharmacy—including	sedatives	or	hypnotics,	
antidepressants, benzodiazepines, and antihypertensive 
drugs—is common in elderly patients but not in young 
adults; these drugs might increase instability and predispose 
patients to a fall.38
•	 Elderly	patients	have	less	brain	reserve	than	younger	
patients,34 a vulnerability that amplifies the result of brain 
damage and hampers rehabilitation.
•	 Pre-existing	neurodegenerative	diseases	that	reduce	
cognitive reserve and impair motor function can increase 
the risk of TBI in affected elderly people.
Cause of injury
•	 Ground-level	falls	and	low-energy	impacts	are	typical	of	TBIs	
in the elderly population,7,26,28,39 and these injuries are 
associated with impaired mobility and polypharmacy.38
•	 TBIs	in	young	adults	are	often	secondary	to	high-energy	
impacts from road traffic accidents or assaults.7,39
Type of lesion
•	 The	proportion	of	subdural	haematomas	diagnosed	in	older	
patients is higher than in young adults; these haematomas 
are typically associated with lower severity and less 
underlying brain injury in older patients.
•	 The	proportion	of	contusions,	epidural	haematomas,	and 
axonal injury lesions diagnosed in young adults is higher 
than in elderly patients.27,28
Clinical course
•	 The	initial	Glasgow	Coma	Scale	score	might	be	
inappropriately high and not reflect the severity of 
structural injury in elderly patients.31
•	 Older	patients	often	have	delays	with	CT	imaging,	are	less	
likely to be transferred to specialist neurosurgical facilities, 
and are more usually cared for by junior medical staff.44
•	 Elderly	patients	have	a	lower	incidence	of	raised	intracranial	
pressure than do younger patients, which could be 
attributable to cerebral atrophy and an increased CSF space 
that buffers new pathological intracranial masses.29,30
•	 Post-traumatic	seizures	are	more	common	in	older	patients	
than in young adults.40
•	 Compared	with	young	adults,	elderly	people	have	poorer	
functional outcomes and higher mortality, more medical 
complications during their stay in the intensive care unit 
(requiring	in-hospital	procedures),	and	longer	hospital	stays	
and continued medical care.27,41–43
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Neurological clinical examination
Clinical examination remains a fundamental monitoring 
procedure, even in patients who are comatose or sedated, 
to identify neurological deterioration and potential 
indications for surgical interventions. The basic 
examination relies on a GCS assessment coupled with 
investigation of pupil diameter and reactivity to light. 
There are some obstacles to a complete GCS assessment: 
tracheal intubation precludes a verbal response and 
facial injuries can impede eye opening, so motor 
response remains the main assessable component of the 
GCS score. Neurological evaluation in patients who are 
deeply sedated can require a sedation hold (wake­up 
test), which might cause arterial hypertension and—in 
patients with reduced intracranial compliance—
transient rises in ICP.45 Whether these ICP spikes are 
detrimental for brain homoeostasis is uncertain.46,47 
Nevertheless, a wake­up test could help to identify 
important clinical changes—eg, signs of progressive 
brainstem impair ment, rapid improvement after 
successful surgical removal of intracranial masses, or 
intoxication with alcohol or other substances. This test 
could affect a patient’s management profoundly, with 
more aggressive intervention in patients who show 
deterioration or shorter intubation and ventilation times 
in those recovering favourably.
Assessments of pupillary diameter and reactivity are 
vital.48 A dilated unreactive pupil usually discloses 
compression of the third cranial nerve due to midline 
shift and uncal herniation.49 Pupillary reaction to light is 
assessed typically using a flashlight, although this 
method has poor inter­rater accuracy in clinical practice.50 
Automated pupillometry is a portable technique that 
measures pupil size and light reactivity automatically and 
with a high degree of precision.51 This method might give 
more accurate measurements of reactivity, particularly 
when the pupil is small (eg, with opioid analgesia).51
Up to 40% of patients with TBI show substantial 
worsening during the first 48 h in the ICU.52 Neurological 
worsening is currently defined as a decrease of 2 points 
on the GCS motor component, pupil asymmetry or loss 
of pupillary reactivity, or deterioration in neurological or 
CT status sufficient to warrant immediate medical or 
surgical intervention.18 Neurological worsening in TBI is 
associated significantly with high ICP and poor 
outcome.53,54 This deterioration is typically due to a new 
or expanding intracranial lesion that might need surgical 
evacuation. Understanding of neurological worsening is 
becoming increasingly important because prompt access 
to early CT means that patients are usually scanned 
within minutes after the TBI, before lesions have had a 
chance to appear or evolve. Parenchymal lesions can 
expand over hours or days: in a series of 352 cases with 
contusions followed up with three CT scans, the volume 
of haemorrhage increased in 42% of patients.55 A routine 
second CT scan is, therefore, recommended for all 
patients with TBI who are comatose, which might 
disclose surgical lesions in up to a third of cases.56 
Additionally, if any substantial clinical worsening occurs 
or ICP rises, a new CT scan must be done.56
ICP monitoring
ICP measurement is done through ventricular or 
intraparenchymal probes connected to a monitor.11 This 
monitoring has been the cornerstone of TBI care since 
the 1980s. However, in a multicentre trial from South 
America (BEST:TRIP),57 ICU management based on 
repeated clinical examination and CT scans was not 
inferior to management including continuous measure­
ment of ICP. It would be entirely inappropriate to discard 
the role of ICP monitoring on the basis of the findings 
of this study,58 but it does highlight the difficulties with 
postulating a direct link between monitoring and 
improvement of outcome, which can be too simplistic 
when considered in isolation.
In the 4th edition of the Brain Trauma Foundation 
guidelines, ICP monitoring is indicated in patients with 
severe TBI, because evidence suggests that ICP­guided 
treatment can reduce early mortality.4 A variable proportion 
of patients with severe TBI develop raised ICP, generally 
depending on the definition. The historical and most 
widely accepted ICP threshold for therapy is 20 mm Hg, 
although the latest guidelines suggest 22 mm Hg.4 This 
approach, which is based on population targets, provides 
little potential for optimising therapy according to the 
needs of individual patients. Indeed, available published 
work suggests that there could be subtle differences in 
critical ICP thresholds between young and old and male 
and female patients, even at an aggregated population 
level, with older patients (age ≥55 years) and females 
having lower ICP thresholds (18 mm Hg vs 22 mm Hg) for 
prediction of poor outcome.59
Protocols for ICP therapy vary in detail but generally 
include prevention of ICP rises using mechanical 
ventilation, sedation, and avoidance of pyrexia (figure 2), 
as well as active interventions.11 For increases in ICP, 
first­tier strategies include oedema management with 
hyperosmotic infusions and drainage of CSF (when a 
ventricular drain is available). More aggressive therapies 
are required for refractory ICP, including hypothermia, 
metabolic suppression with deep sedation, decompressive 
craniectomy, and hypocapnia, but these can have harmful 
side­effects (figure 2).60,61 ICP monitoring is fairly safe; 
complications such as haemorrhage and infection arise 
in 1–7% of cases,62 driving a search for non­invasive 
alternatives. Several methods are under investigation for 
non­invasive ICP measurement but are not yet ready for 
clinical use.11
Maintenance of cerebral homoeostasis
Maintenance of cerebral homoeostasis and, in particular, 
optimisation of cerebral oxygen supply and demand are 
traditionally attempted using indirect variables such as 
cerebral perfusion pressure (CPP), which is the difference 
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between mean arterial blood pressure and ICP. Ideally, 
normal arterial pressure coupled with a physiological ICP 
value should be maintained. In cases of arterial 
hypotension, vasopressors and volume expansion are used 
to restore an adequate arterial pressure whereas ICP 
becomes a target when it exceeds a threshold. CPP of 
around 60 mm Hg is generally targeted, although the 
latest guidelines suggest some discrimination between 
individuals with and without preserved autoregulation.4 
However, as with ICP, these guidelines do not account for 
differences in CPP thresholds between groups of patients.59
Modulatory effects of age
A clear association has been noted between older age and 
worse outcome,42,43 which could be accounted for, at least 
in part, by the effects of age­related comorbidities,63 use 
of pharmacotherapies to treat comorbidities (particularly 
antithrombotic drugs),37 and reduced brain reserve in 
elderly patients.34 Treatment and monitoring of 
comorbidities might, therefore, be as important as 
management of TBI in determining outcome.63 
Treatment of drug­induced coagulopathy with reversal of 
anticoagulant or antiplatelet therapy is essential if an 
intracranial haemorrhage is present.64,65 Post­traumatic 
seizures are common in older patients with TBI;40 
however, the optimum therapy and length of seizure 
prophylaxis in this population is still not clear.
An unfavourable outcome in older patients could be, at 
least in part, a self­fulfilling prophecy. Data gathered for 
4387 patients with TBI in the UK indicate suboptimum 
care for older patients, including delayed CT scans, 
assessment more commonly by junior medical staff, and a 
reduced likelihood of being transferred to neurotrauma 
centres (panel).44 However, when older patients are treated 
aggressively and promptly after admission to the ICU, 
favourable outcomes are seen in 39% of patients aged 
60–69 years,27 suggesting that this nihilistic attitude is not 
justified.
The lower ICP threshold associated with poor outcome 
in older patients compared with younger people 
(18 mm Hg vs 22 mm Hg)59 might reflect the greater 
vulnerability of the aged brain, or a given rise in ICP 
might denote a worse brain injury in older patients, since 
age­related atrophy and increased CSF space allows 
lesion expansion and brain oedema before ICP rises. 
Notwithstanding the cause, these data provide the 
rationale for investigating whether a reduced threshold for 
ICP control might be beneficial in older patients. However, 
because increased ICP is less frequent in elderly 
populations, and tissue penetration by intracranial probes 
is riskier in patients who have received anticoagulant and 
antiplatelet drugs, there is a case for revised (reduced) 
indications for ICP monitoring in these patients.
Elderly patients might also have compromised 
autoregulation because of arterial hypertension, with the 
autoregulatory curve shifted towards higher arterial 
pressure. Indeed, available data suggest that CPP 
thresholds for survival are higher in patients older than 
55 years than in younger patients,59 and a higher CPP 
might be desirable, particularly in patients with a history 
of arterial hypertension.4,59
It is worth noting that the current conceptual basis of 
ICU management of TBI is based on a body of experience 
accumulated over the past four decades, which derives 
overwhelmingly from younger patients with high­velocity 
injuries. It would be wrong, or at least unsafe, to assume 
that this experience can be directly applied to the older 
patients we see with different injury mechanisms (panel), 
and there is a pressing need to develop optimum 
management strategies targeted to these patients.
Targeted ICU management based on 
physiological monitoring
Clinical pathophysiology of TBI is dependent on the 
patient, the treatment given, and the type of injury and, 
therefore, is highly heterogeneous. A one­size­fits­all 
management strategy is unlikely to be optimum. More 
precise understanding of intracranial disturbances might 
indicate specific targets and, hopefully, targeted therapies. 
A panoply of monitoring techniques (table 1) and imaging 
modalities (table 2) can be used to obtain this information, 
including measurement of brain tissue partial tension 
Figure 2: Current prevention and treatment of intracranial hypertension after traumatic brain injury
Surgical removal of intracranial masses is the most effective treatment for intracranial hypertension in the early 
phases after TBI. After surgery, strategies for ICP control are graded from prevention to progressively more 
intensive treatments. Prevention of high ICP is based on standard procedures in the intensive care unit, with fairly 
modest	side-effects,	such	as	ventilator-associated	pneumonia	for	prolonged	artificial	ventilation.	First-tier	active	
interventions include CSF withdrawal (which requires a ventricular drain, with the risk of ventriculitis) and 
hyperosmolar drugs, such as mannitol or hypertonic saline (with the risks of cardiac overload during infusion and 
dehydration and hyperosmolar states due to induced diuresis).11	Second-tier	interventions	include	more	aggressive	
treatments with associated risk of severe complications. Preventive measures are usually used for all patients with 
severe TBI, whereas active treatment is triggered by ICP rises. This approach is based mainly on clinical experience 
rather than on strong published evidence.4	Because	of	side-effects,	interventions	effective	at	reducing	ICP	might	
not translate directly into improved outcomes.60,61 ICP=intracranial pressure. TBI=traumatic brain injury.
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of oxygen (PbtO2), microdialysis, and autoregulation 
assessment.66 In isolation, these techniques generally 
provide indirect measures of TBI pathological processes. 
For example, raised ICP is not a diagnosis by itself: it 
results from many (usually co existing) mechanisms, 
including oedema (either cytotoxic or vasogenic), increased 
cerebral blood volume (which itself might result from 
many disparate mechanisms, including excessive meta­
bolic demand, hypercapnia, or disordered auto regulation), 
or impaired CSF reabsorption. Methods to better 
characterise pathophysiological derangements have been 
available in the past two decades; however, they have been 
used rarely, even in the most specialised neurological 
ICUs. Findings of a survey of 31 specialised ICUs in the 
UK showed that ICP monitoring was used frequently in all 
but one institution, PbtO2 measurement in eight (26%), 
and microdialysis in only four (13%) centres.67 
Measurement of PbtO2
ICP and CPP provide information on the driving 
pressure for blood flow through the cerebral circulation. 
However, downstream metabolic events can also be 
monitored using several probes, typically through a 
common insertion device. One such example is 
measurement of PbtO2,68–70 which provides a continuous 
(albeit localised) spatial average of extracellular oxygen 
tension as an indicator of the adequacy of oxygen delivery. 
PbtO2 depends on the balance between oxygen delivery 
and consumption, and the cerebral metabolic rate of 
oxygen. It is affected further by the ability of oxygen to 
diffuse.71,72 For example, in pericontusional tissue, 
diffusion of oxygen might be affected not only by tissue 
and endothelial oedema but also by microvascular 
collapse, which increases the mean intercapillary 
distance for diffusion, reducing average oxygen tension.72
Determining appropriate target values for PbtO2 is clearly 
methodologically difficult: oxygen tensions of around 
23 mm Hg are recorded during or after functional 
neurosurgery.73 Values between 15 mm Hg and 20 mm Hg 
are typically regarded as thresholds for inadequate oxygen 
supply74–76 and are associated with worse outcome after 
TBI.72 Therapeutic approaches have been described that 
aim to return PbtO2 to normal levels by increasing either 
arterial pressure or arterial oxygen tension, or both.77,78 
Those strategies seem to be associated with better outcomes 
than strategies focused only on ICP and CPP. However, 
without large controlled trials, evidence is inconclusive.79
Microdialysis
Measurement of glucose, lactate, and pyruvate in the 
extracellular space of the brain using cerebral micro­
dialysis provides information on energy metabolism. 
A high lactate:pyruvate ratio after TBI is a marker 
of anaerobic glucose utilisation, resulting from low PbtO2 
due to ischaemia or diffusion hypoxia or, under normoxic 
conditions, mitochondrial dysfunction.80–82 A high 
Variable monitored Variable derived Focal or 
global 
measure
Time resolution Risk of 
brain 
damage
Running costs (€)* Other limitations
Intracranial pressure monitoring 
with intraparenchymal monitor 
or ventricular catheter
Intracranial pressure Intracranial volumes, cerebral 
perfusion	pressure,	pressure-reactivity	
index, intracranial compliance
Global Continuous Yes <50 None
Brain tissue oxygen measurement 
with parenchymal probe
Brain tissue partial 
tension of oxygen
Oxygen diffusion and balance 
between oxygen supply and demand
Focal Continuous Yes 50–500 None
Cerebral microdialysis Brain metabolites and 
biomarkers
Aerobic or anaerobic metabolism, 
brain injury severity and inflammation
Focal Intermittent Yes >500 None
Temperature monitoring via 
intraparenchymal probe
Brain temperature Gradient between core and brain 
temperature
Focal Continuous Yes 50–500 None
Intraparenchymal thermal 
diffusion flowmetry
Cerebral blood flow Hypoperfusion or hyperperfusion Focal Continuous Yes >500 Non-standard	
technique
Electrocorticography Cortical and depth 
electrical activity
Seizure activity, spreading 
depolarisation
Focal Continuous Yes >500 Requires specific 
surgical placement
Jugular bulb oximetry Oxygen saturation of 
venous jugular 
haemoglobin
Cerebral arterojugular difference in 
oxygen content
Global Intermittent 
(continuous with 
fibreoptic catheters)
No <50 (50–500 for 
fibreoptic 
catheters)
None
EEG Cortical electrical activity Seizure activity, abnormal patterns Global Continuous No <50 Training needed
Transcranial doppler Cerebral blood velocity Critical closing pressure, cerebral 
arterial impedance
Global Intermittent No <50 Operator-dependent
Optic-nerve	sheath	
ultrasonography
Optic	nerve-sheath	
diameter
Intracranial pressure Global Intermittent No <50 Operator-dependent
Near-infrared	spectroscopy Cerebrovascular oxygen 
saturation and relative 
blood volume
Cerebral blood flow, cerebral 
autoregulation
Focal Continuous No 50–500 Extracerebral 
contamination 
of signal
The most commonly used bedside technologies are listed.66 *Based on information provided by device vendors in most European countries; monitors, personnel, and maintenance are not considered. 
Table 1: Current bedside neuromonitoring modalities for traumatic brain injury
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lactate:pyruvate ratio indicates an energy metabolism 
crisis and is an independent predictor of mortality.83 
Improvement in the lactate:pyruvate ratio might indicate 
a beneficial effect of treatment. The effects of various 
interventions—eg, hyperoxia and hypertonic lactate—on 
brain energy metabolism have been investigated. 
Normobaric hyperoxia, which is usually induced by 
increasing the fraction of inspired oxygen, can typically 
raise a low PbtO2, but inconsistent benefits on micro­
dialysis variables have been reported.84,85 However, 
findings of imaging studies suggest improvements in the 
cerebral metabolic rate of oxygen86 and reversal of 
pericontusional cytotoxic oedema with this intervention.87 
Attempts to improve brain glucose metabolism with 
hypertonic lactate infusions show a clear cerebral glucose­
sparing effect, but mainly in patients with a pathological 
lactate:pyruvate ratio.88 These preliminary clinical trial 
results need to be confirmed with larger numbers of 
participants, but early findings indicate the possibility for 
targeted interventions.
Autoregulation assessment
Methods for online real­time assessment of cerebro­
vascular autoregulation, a physiological mechanism that 
serves to maintain adequate cerebral perfusion in the 
presence of blood pressure changes, have been studied.66 
Under typical conditions, with normal autoregulation, 
the diameter of cerebral vessels changes to adjust for 
alterations in arterial pressure (eg, vasoconstriction in 
response to arterial hypertension) and these changes can 
affect ICP. In the case of vasoconstriction, ICP should 
remain unaffected or it could decrease. ICP 
measurements can, therefore, be used to assess how 
brain vessels react to variations in arterial pressure. In 
pathological conditions such as severe TBI, auto­
regulation can be altered or totally lost. Probably the best 
known measurement is the pressure­reactivity index 
(PRx)—ie, the correlation coefficient between ICP and 
arterial pressure readings using a moving data window, 
which is usually a negative number.89–91 The PRx typically 
shows a U­shaped relation when plotted against 
spontaneous changes in CPP over time, with the lowest 
PRx noted in the optimum autoregulatory range. The 
CPP for which the PRx is a minimum is, therefore, 
deemed to represent a state of optimum autoregulation, 
and CPP­based management that targets this level has 
been associated with better outcomes.92,93
An autoregulation­guided approach to individualise 
CPP might be helpful in preventing cerebral hypo­
perfusion while avoiding the risks of excessive cerebral 
blood flow. An approach based on optimisation of 
autoregulation is physiologically attractive and has the 
potential to reconcile perfusion­supporting and oedema­
minimising treatments. However, autoregulation can be 
impaired in a region­specific way that might not be 
captured by the PRx, which is a global average. Alternative 
measures based on assessment of blood flow or brain 
tissue oxygen reactivity have the opposite limitation of 
restricted global spatial coverage. Prospective evidence 
from clinical studies is urgently needed before definitive 
guidelines can be drawn up.
Multimodal monitoring for individualised management
Simultaneous use of several monitoring modalities could 
provide a means of targeting patient­specific ICP 
thresholds.66 Concordant changes identified from different 
measures provide cross­validation of the physiological 
state of the injured brain. For example, a critical PbtO2 
reduction could be used to individualise thresholds for 
more aggressive methods for correcting low CPP due to 
high ICP. Conversely, discordant findings, although 
potentially posing a clinical dilemma in terms of treatment 
compromise, might sometimes offer clues to the presence 
of pathophysiological heterogeneity and stimulate the 
Variable monitored Information derived Spatial 
resolution
Radiation 
absorption
Acquisition 
time (min)
Other limitations
CT Structural integrity Space-occupying	lesions,	CSF	space	
modifications, skull fractures, 
brain swelling
Medium Low <5 Limited resolution 
for posterior fossa 
pathology
CT angiography Cerebral vessel 
patency and integrity
Thrombosis and dissection in main 
intracranial vessels
Medium Medium <5 Contrast medium 
injection needed
Perfusion CT Cerebral perfusion Hypoperfusion or hyperperfusion Low High <5 Contrast medium 
injection needed
MRI Structural, functional, 
and biochemical 
integrity, cerebral 
vessel patency
Space-occupying	lesions,	CSF	space	
modifications, brain swelling, 
thrombosis and dissection in main 
intracranial vessels, hypoperfusion or 
hyperperfusion, traumatic axonal 
injury, functional and chemical 
information
High None >20 Magnetic field 
environment might 
be contraindicated 
in some patients,* 
high cost
*MRI use is not possible in patients who have indwelling probes containing ferromagnetic material or in patients who are dependent on ventilators, infusion pumps, or 
monitors used in the intensive care unit for which magnetic resonance safety is unknown. Some magnetic resonance studies can be prolonged and might be contraindicated 
in unstable patients. 
Table 2: Current imaging modalities for traumatic brain injury
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search for less well recognised routes to energy failure, 
such as diffusion hypoxia,71,72 mitochondrial dysfunction,94 
and low cerebral glucose levels83,95 as downstream markers 
of compromised cerebral perfusion.
However, current multimodal monitoring generates 
vast amounts of data, which might need to be summarised 
for clinicians to extract information that can be used to 
guide patients’ care (figure 3). Advances in monitoring 
will probably also depend on advances in neuroinformatics 
and data analysis.96 Computer visualisation techniques 
offer a promising way to reduce complex datasets to a 
form that can be interpreted by clinicians and have been 
applied in various areas, including investigation of the 
cumulative burden of intracranial hypertension97 and 
assessment of autoregulation.98 Such complex multi­
dimensional problems are not new outside medicine, and 
other so­called big data techniques will very likely find 
increasing application in the intensive care of patients 
with TBI.99
Physiological monitoring in elderly people
Use of advanced multimodal monitoring to guide 
management in older patients is conceptually appealing, 
but experience in this area is scarce. This lack of 
experience is in part accounted for by the increased 
risks of invasive intracranial monitoring in older 
patients, who frequently present on anticoagulant and 
antiplatelet drugs (panel), and in part by the expectation 
of poor outcome that has made aggressive monitoring 
and therapy less frequent in this age group. Changing 
attitudes might provide more data to guide 
individualisation of treatment for older patients in the 
future, and development of less invasive monitoring 
methods would be particularly beneficial in this group.
Targeted ICU management with aggressive 
therapies
No treatments in the ICU are risk free, and the more 
aggressive interventions for restoring cerebral homoeo­
stasis have substantial potential to cause harm (figure 2). 
Multimodal monitoring can show that aggressive 
interventions are justified by proving that cerebrovascular 
physiology is seriously compromised (eg, ICP and CPP 
outside the thresholds, PbtO2 reductions, or elevations in 
lactate and lactate:pyruvate ratio), and not amenable to 
therapy with less risky interventions. Once a therapeutic 
Figure 3: Screenshot showing computerised multimodal monitoring for traumatic brain injury
Advanced invasive monitoring for patients with traumatic brain injury (TBI) can simultaneously provide time trends for mean intracranial pressure (ICP), arterial 
blood	pressure	(ABP)	readings,	the	pressure-reactivity	index	(PRx),	a	derived	autoregulation	index	(presented	both	as	a	time	trend	and	as	a	colour-coded	warning	
bar), measures of brain tissue partial tension of oxygen (PbtO2), and three microdialysis variables (glycerol [GLY], lactate:pyruvate ratio [LPR], and glucose [GLC]), all 
shown in the first column. It is helpful to integrate the signals into one bedside screen with trend charts showing current and historical values to allow early detection 
and accurate assessment of newly developing second insults. Other crucial information can be obtained from the neuromonitoring signals and presented on the 
same screen (second column) to further facilitate decision making. This includes information about the current (and historical) state of cerebral autoregulation and 
the related cerebral perfusion pressure (CPP) safe zone recommendation. These are depicted in the second column as CPP; end tidal CO2 (an estimate of partial 
pressure of CO2 in the blood [ETCO2]); two optimum CPP representations (the estimated CPP range corresponding to intact autoregulation [in green] and an error bar 
chart summarising the PRx /CPP relation [the optimum CPP value is at the vertex of the fitted curve]); and the time percentage of a given CPP value (represented by 
the histogram at the bottom of the second column). Total (or recent) doses of intracranial hypertension or brain hypoxia (as indicated by PRx, ICP, and PbtO2, with 
insult regions highlighted in red), and the state of homoeostatic decomplexification (as indicated by the ICP complexity chart [CI(ICP)], 
a multiscale entropy representation) are shown in the third column.
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target has been identified, careful measurement of 
physiological variables can minimise harm for some 
interventions.
Augmentation of CPP
Pharmacological augmentation of CPP might improve 
cerebral oxygenation but at the expense of serious 
cardiopulmonary complications.100 Advanced cardio­
vascular monitoring—including intravascular volume 
assessment, echocardiography, or cardiac output—
beyond standard pulse oximetry and invasive arterial 
pressure monitoring might be necessary.66
Hypocapnia
A brief period of hypocapnia could be justifiable in the 
face of an episode of dangerously high ICP but it might 
cause ischaemia through vasoconstriction,101 particularly 
in the early phases after injury. For this reason, 
measurement of cerebral oxygenation—most commonly 
by PbtO2 monitoring—is recommended when hypocapnia 
is used, to minimise the ischaemic risk.66
Metabolic suppression
Barbiturates for metabolic suppression are effective in 
reducing ICP but carry substantial risks of cardiovascular 
instability and other end­organ dysfunction or metabolic 
disturbances.102 Advanced cardiovascular monitoring 
and support—including fluid titration, inotropes, and 
use of vasopressors—is advisable to avoid arterial 
hypotension.
Hypothermia
Hypothermia, a treatment with strong neuroprotective 
action in animal models,103 failed to show outcome benefit 
in clinical trials.61 When moderate hypothermia (32–35°C) 
was used as an early ICP intervention, the treated group 
had a worse outcome than did controls.61 Despite the 
results of this trial, hypothermia continues to be used in 
some centres but typically with higher ICP thresholds 
(25–30 mm Hg),104 denoting an implicit acceptance that the 
risks of hypothermia demand more deranged physiology 
before the risk:benefit ratio becomes favourable.
Decompressive craniectomy
Decompressive craniectomy is effective at reducing ICP, 
but results of RCTs have shown differences in outcome 
depending on the target group. In the DECRA trial,60 
decompressive craniectomy did not improve outcome 
when used for modest ICP increases. However, the 
balance of risk and benefit changes in circumstances for 
which aggressive therapies are justified by the presence 
of refractory severe intracranial hypertension. For 
example, in the RESCUE­ICP study,105 decompressive 
craniectomy targeted to patients with refractory severe 
ICP was shown to reduce mortality and shift neurological 
outcomes so that more patients could at least function 
independently at home, although these gains were 
achieved at the expense of increases in survival with 
severe disability.
These findings emphasise the importance of following 
a graded sequence for aggressive interventions, beginning 
with those with least potential for harm before escalating 
to higher—and potentially more harmful—therapeutic 
intensity (figure 2). Furthermore, the evidence highlights 
the need to select interventions on the basis of the clinical 
picture in individual patients and the circumstances at 
the time of intervention. Further research into the 
contribution of the physiological monitoring methods 
might enable more refined stratification of patients for 
these more aggressive therapies.
Aggressive therapies in elderly patients
Aggressive therapies are linked to severe side­effects and 
might not be tolerated by frail older patients with 
impaired physiological reserve (panel). The high 
incidence of cardiorespiratory comorbidities in such 
individuals might further reduce the ability of patients to 
tolerate some of the aggressive interventions (eg, 
augmentation of CPP, barbiturates, and hypothermia) 
used in the critical care of TBI. Therefore, careful 
monitoring of systemic physiology is mandatory, and 
caution is needed with haemodynamic augmentation 
and second­tier therapies for high ICP in these patients.
In two major RCTs on decompressive craniectomy for 
TBI,60,105 patients older than 65 years were excluded, 
probably reflecting the scepticism of the neurotrauma 
community about use of aggressive therapies in older 
people. In another study, decompressive craniectomy 
was used to treat unilateral or bilateral brain swelling in 
44 patients with TBI older than 66 years;106 however, 
mortality was 77% and overall unfavourable outcomes 
were recorded in 82%, leading to this approach being 
abandoned in clinical practice for elderly patients who 
present with a GCS of 8 or less.
Emerging opportunities in the management of 
severe TBI
The focus of this Review has been on how we might 
improve clinical management of TBI using techniques 
that are already available, even if not used widely in 
clinical practice. However, emerging advances could 
deliver additional refinement, or even paradigm changes, 
in how we treat these patients, with respect to better 
characterisation of TBI, identification of novel therapeutic 
targets, and generation of evidence to support changes in 
management. Pharmacological trials of erythropoietin107,108 
and progesterone109,110 for TBI failed to show improvement 
in neurological outcome despite experimental evidence of 
multiple neuroprotective mechanisms, thus under lining 
the importance of targeting treatments to selected groups 
of patients. Enrolment criteria in these trials were based 
on severity of TBI, and the benefits of compounds acting 
on specific pathways might not have been demonstrable 
in a heterogeneous population of patients with TBI. 
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Future trials should aim to select patients on the basis of 
specific mechanisms of brain damage in individual 
patients to maximise potential for improved outcomes.
The growing use of MRI in TBI promises to provide 
better definitions of injury location, type, and severity;111 
moreover, accumulating data linking genetic variability 
to outcome112 suggest that we might be able to identify 
patients in whom specific therapies could be effective. 
For instance, once the pathological role of spreading 
depression is clarified better and patient groups who are 
likely to be affected have been identified, specific 
interventions—eg, nimodipine or ketamine—could be 
envisaged to correct spreading depression.113 Promising 
therapeutic targets are emerging from more rigorous 
preclinical evaluation of new interventions for TBI, such 
as those delivered by Operation Brain Trauma Therapy, a 
multicentre multiplatform collaboration for experimental 
evaluation of therapies.114 Other basic biology research 
that might advance clinical interventions for mitigation 
of secondary injury includes identification of the 
sulfonylurea receptor (SUR1), which is implicated in 
oedema formation and contusion expansion,115 preclinical 
assessment of novel brain fuels that bypass impaired 
energy metabolism,116 and more precise targeting of the 
inflammatory response,117 which is emerging as a key 
player in TBI pathophysiology.
Conclusions and future directions
Advances in monitoring provide a paradigm that could 
enable us to move treatment of TBI in the ICU from a 
standard one­size­fits­all approach to more individualised 
treatment. Better identification of disease mechanisms 
as potential targets for intervention seems a reasonable 
aspiration. Improved characterisation of mechanisms 
might also offer new goals for neuroprotective drug 
development. However, translational failure of a few 
biologically and experimentally well founded inter­
ventions118 suggests that uncharacterised patient factors 
are still a major stumbling block in terms of tailoring 
aggressive treatments to maximise benefit and minimise 
harm at an individual level. Despite the wealth of data, 
stratification of patients into subgroups with more 
homogeneous pathophysiology, disease course, and 
expected outcome is still at an early stage.
Integration of newer monitoring modalities could 
provide further individualisation of therapy, but these 
approaches rely on data that do not come from RCTs 
based on targeted approaches. Indeed, the results and 
subsequent discussion of the BEST:TRIP trial of ICP 
monitoring57,58 highlight the difficulties with using classic 
RCTs to evaluate monitoring devices and treatment 
thresholds, and we might need to rely on other means of 
evidence generation—eg, comparative effectiveness 
research—to provide strong frameworks for use of newer 
monitoring devices in TBI. Such approaches will need 
large, well characterised populations of patients with 
rigorous outcome assessment. International initiatives—
eg, the Collaborative European NeuroTrauma Effectiveness 
Research in TBI (CENTER­TBI) and other partner studies 
in the International Traumatic Brain Injury Research 
initiative (InTBIR)—could generate the large samples 
needed to address this aim and provide the context for 
developing and testing precision medicine approaches in 
severe TBI.
The epidemiological shift towards a larger proportion of 
physiologically fragile elderly patients with TBI in high­
income countries calls for varying preventive approaches, 
such as measures aimed at frailty and falls,119 and suggests 
the need for changes in ICU management approaches. 
Less­invasive monitoring methods, for instance, might 
improve care and reduce side­effects during the acute 
phase. Techniques for quick and efficient restoration of 
coagulation could limit brain injury progression in 
patients on anticoagulant and antiplatelet drugs, thus 
improving outcomes. Provision of care based on 
measured, rather than assumed, outcome could avoid 
self­fulfilling prophecies of inevitable poor outcome for 
older patients. Age older than 65 years has often been an 
exclusion criterion in clinical trials of interventions for 
TBI—eg, decompressive craniectomy and neuroprotective 
drugs52,60,105,108,120—leading to the paradox that a population 
segment at increased risk of TBI has not been exposed to 
possible therapeutic interventions. In view of the logistic 
complexities of undertaking RCTs in TBI generally, and 
specifically in older patients, comparative effectiveness 
research approaches might also facilitate assessment of 
interventions in older patients, with differences in 
management of these individuals in various centres 
providing an appropriate context to undertake such 
studies.
The changes described here hold promise for reshaping 
current management in the ICU and potentially 
improving outcome. However, showing that this promise 
can be fulfilled requires rigorous research evaluation and 
proof of cost­effectiveness.
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